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Turning Up the Heat on Malignant Hyperthermia
Katie Carroll, RN, BSN, CCRN
Otterbein University, Westerville, Ohio
Introduction
Surgeries are common, everyday
procedures within the walls of America’s
hospitals. According to Orser, Mazer, and
Baker (2008), more than forty million
patients in North America are given
anesthetics annually. One of the major
complications of anesthesia is malignant
hyperthermia: a hyper-metabolic state
that affects skeletal muscles. If left
uncontrolled, malignant hyperthermia
can cause multiple reactions within the
body leading to metabolic and
respiratory acidosis, cardiac
dysrhythmias, kidney failure,
coagulopathy, neurologic injury, and
ultimately death (Seifert, Wahr, Pace,
Cochrane, & Bagnola 2014). The
incidence of this condition is estimated to
be 1:15,000 in children and 1:20,00050,000 in adults (Redmond, 2001).
Although considered a rare event, the
mortality rate of malignant hyperthermia
was eighty percent in 1960 and has
steadily declined to less than ten percent
by 1980 (Saleh, 1992). The concern,
however, revolves around the facts that
malignant hyperthermia is a hereditary
condition that is difficult to screen for
prior to the administration of anesthesia,
and it occurs in every country and race,
male and female, child and adult
(Donnelly, 1994). Prompt intervention is
crucial and can adequately impede the
progression of this heightened metabolic
state, yet, delayed action will quickly
increase risk of death (Redmond, 2001).
Therefore, continued education in
regards to the pathophysiology of
malignant hyperthermia will aid the
surgical team in identifying risk factors,
recognizing early signs, and interceding
appropriately to protect patients from a
potentially life-threatening reaction.

Pathophysiological Processes
Malignant Hyperthermia (MH) is
considered a pharmacogenetic disorder
as it is an autosomal dominant disorder
activated by the introduction of certain
anesthetic agents solely or in
conjunction with a neuromuscular
blocker known as succinylcholine
(Stratman, Flynn, & Hatton, 2009).
Those genetically susceptible have a
defect of the ryanodine receptor (RYR
1), which encodes for the calcium
channel on the sarcoplasmic reticulum
of skeletal muscle cells. Once triggered
by anesthesia agents, there is an
exaggerated release of calcium resulting
in a cascade of potentially lethal
reactions. Uncontrolled increase in
calcium stimulates actin and myosin to
produce prolonged muscle contractions
leading to accelerated adenosine
triphosphate (ATP) depletion; oxygen
consumption; glucose metabolism;
lactate, carbon dioxide, and heat
production. Consequently, acidosis,
hyperthermia, and dangerously low ATP
levels ensue thus causing the
sarcolemma of the muscle cells to
become damaged, cell death occurs, and
intracellular contents such as
magnesium, potassium, phosphate, and
myoglobin are leaked systemically. The
domino effect described places the
patient in a hyper-metabolic state with
potential for multiple organ damage and
failure (Stratman et al., 2009).

Meanwhile, the hyper-metabolic state
perpetuates the rise in body temperature
potentiating the risk for coagulation
disorders such as disseminated
intravascular coagulopathy and neurologic
damage (Dirksen, Van Wicklin, Mashman,
Neiderer, Merritt, 2013). However, the
pathophysiology of MH can be significant
in a positive way as it identifies what
interventions will be effective in hindering
the devastating pathway from continuing.
For example, understanding the genetic
origin of MH has led to genetic testing to
identify those susceptible, knowledge of
the sustained muscle contraction that
occurs and begins the lethal progression
has led to the use of dantrolene, a muscle
relaxant, as the first-line treatment
(Stratman et al., 2009), and the awareness
of the systemic effects have led to
numerous interventions to prevent a
secondary injury (Dirksen et al., 2013).
Therefore, understanding the
pathophysiology of MH can help direct the
perioperative team to prompt recognition
and appropriate treatment of such a
destructive disorder.

Case Study
A 22 year old male presented to a
military hospital after being injured by an
improvised explosive device. He
presented with a penetrating injury to his
left thigh; radiological findings confirmed
a left femur fracture. The patient was
conscious and able to answer questions;
he denied any allergies or past medical
history. The man was prepared for
surgery and given ketamine, 50 mg;
etomidate, 30 mg; and succhinylcholine,
120mg for rapid sequence intubation.
Post-intubation vitals are as follows:
blood pressure (BP) 115/60 mmHg;
heart rate (HR) 90/min; arterial oxygen
saturation (Sao2) 100%; end tidal carbon
dioxide (ETCO2) 42 mmHg;
temperature 98.6 degrees F. General
anesthesia was maintained with
sevoflurane. Total operative time was
two hours with no complications.

However, upon completion, the BP was
118/42; HR 106; Sao2 100%, ETCO2 65;
and temp 100.4F. Pain medicine was given
for increased heart rate yet fifteen minutes
later the ETCO2 was 90, BP 140/78; HR
110, temp 100.6. Hyperventilation was
initiated to reduce ETCO2, and the
anesthesia machine was inspected but no
malfunction found. Concurrently, severe
bilateral masseter muscle contractions and
increased abdominal muscle rigidity were
noted. The temperature climbed to 100.9F,
labs were sent revealing hyperkalemia and
a diagnosis of MH was made. The patient
was then given dantrolene, 2.5mg/kg. Once
the dantrolene bolus was given, muscular
rigidity disappeared. Twenty minutes
following bolus, ETCO2 was 35 and
temperature was 100.5F, all other vital
signs were stable. Seventy minutes after
treatment, the patient was completely
stable and was transported to another
facility (Banet, Weatherwax, Spence, Perry,
Muldoon & Capacchione, 2013).

Signs and Symptoms
Unfortunately, other diseases such as
thyroid storm, heat stroke,
pheochromocytoma, cocaine overdose,
etc. can present in phenotypically similar
ways as MH making timely diagnosis a
challenge. Moreover, many genetically
susceptible patients undergoing general
anesthesia are unaware of their genetic
defect; it is likely there will be no
forewarning of this rapidly debilitating
disorder. Therefore, detection of the
signs and symptoms of malignant
hyperthermia is imperative for the
healthcare team in order to improve
patient survival. The signs and symptoms
for MH can be classified as either early or
late. Typically, the earliest signs can
occur within minutes of exposure and
include: increased end tidal carbon
dioxide, tachycardia, and contraction of
the masseter muscle of the jaw. Other
early signs are tachypnea, generalized
muscle rigidity, cardiac arrhythmias, and
electrolyte imbalances.

Late signs can occur hours after
exposure and are associated with
mottled skin, disseminated intravascular
coagulation, rhabdomyolysis,
myoglobinuria, renal failure, respiratory
and metabolic acidosis, and
hyperthermia. Once hyperthermia sets
in, shock and lethal arrhythmias can
occur as quickly as twenty minutes due
to oxygen consumption that is two to
three times the normal rate of
consumption (Stratman et al., 2009). All
in all, the longer the disorder has to
disturb the body’s homeostasis, the
harder it is to combat. Early detection is
paramount when dealing with malignant
hyperthermia.

Nursing Implications
Malignant hyperthermia is a rare and
fatal disorder that can be challenging to
detect and treat. Due to the low incidence
of MH events, medical personnel are
often not familiar and/or confident in the
management of such an event. Therefore,
it is the responsibility of the healthcare
team to familiarize themselves with the
disorder, the signs and symptoms,
expected treatments, and evaluation of
successful intervention. A study was
done in the Midwest with all surgical
personnel being placed in various
simulations that were set to resemble a
malignant hyperthermia crisis. The staff
was educated on the disorder, simulation
was completed, and all members were
debriefed. The findings produced
protocols and exercises that are done on
a monthly basis to ensure all parties of
the OR team are prepared for MH if it
should arise. One recommendation that
was vital to the teams was assigning each
person with a specific task in order to
accomplish all the interventions needed
to safely care for a MH patient. For
example, multiple members needed to
dilute dantrolene as this can be a tedious
step, another cooled the patient with ice,
another documented the event, etc.
(Cain, Reiss, Gettrust, & Novalija, 2014).
PACU and ICU nurses also need to be
educated as many signs and symptoms
of MH may not present in the OR but in
the PACU or critical care units (Barnes,
Stowell, Bulger, Langton, & Pollock,
2015). Nurses need to provide education
for the patients and families of those
whom have suffered with MH, assuring
they understand how critical this
disorder can be and how pertinent it is
that they allow future anesthesia teams
know of their susceptibility to the deadly
disorder.

Conclusion
Malignant hyperthermia is a
complex, life-threatening crisis that
.
presents multiple challenges yet can
be successfully impeded with rapid
and proper treatment. Continued
education is essential for early
detection, educated planning, swift
implementation, and proficient
evaluation of an MH event. Thorough
pre-operative assessments, strong
intra-operative knowledge, and
efficient interdisciplinary roles will
only bolster the fight against MH and
ensure significant reduction in
morbidity and mortality (Stratman et
al., 2009).

References
Banek, L. R., Weatherwax, L. J., Spence, U.
C. D., Perry, L. S., Muldoon, S., &
Capacchione, J. (2013). Delayed Onset of
Suspected Malignant Hyperthermia
During Sevoflurane Anesthesia in an
Afghan Trauma Patient: A Case Report.
AANA journal, 81(6), 441.
Barnes, C., Stowell, K. M., Bulger, T.,
Langton, E., & Pollock, N. (2015). Safe
duration of postoperative monitoring for
malignant hyperthermia patients
administered non-triggering
anaesthesia: an update. Anaesthesia and
intensive care, 43(1), 98-104.
Brownstown Biomes (2015).
[Thermometer]. Retrieved from
brownstownbiomes.wikispaces.com.
Cain, C. L., Riess, M. L., Gettrust, L., &
Novalija, J. (2014). Malignant
hyperthermia crisis: optimizing patient
outcomes through simulation and
interdisciplinary collaboration. AORN
journal, 99(2), 300-311.
Dirksen, S. J. H., Van Wicklin, S. A.,
Mashman, D. L., Neiderer, P., & Merritt,
D. R. (2013). Developing effective drills
in preparation for a malignant
hyperthermia crisis. AORN journal,
97(3), 329-353.
Donnelly, A. J. (1994). Malignant
hyperthermia: epidemiology,
pathophysiology, treatment. AORN
journal, 59(2), 393-405.
Katielyn & Kelsey (2015). [sliding
filament theory]. Retrieved from
www.katelynanderson.wikispaces.com
Orser, B. A., Mazer, C. D., & Baker, A. J.
(2008). Awareness during anesthesia.
Canadian Medical Association Journal,
178(2), 185-188.
Redmond, M. C. (2001). Malignant
hyperthermia: perianesthesia
recognition, treatment, and care. Journal
of PeriAnesthesia Nursing, 16(4), 259270.
Saleh, K. L. (1992). Practical points in the
management of malignant hyperthermia.
Journal of post anesthesia nursing, 7(5),
327.
Seifert, P. C., Wahr, J. A., Pace, M.,
Cochrane, A. B., & Bagnola, A. J. (2014).
Crisis Management of Malignant
Hyperthermia in the OR. AORN journal,
100(2), 189-202.
Stratman, R. C., Flynn, J. D., & Hatton, K.
W. (2009). Malignant hyperthermia: a
pharmacogenetic disorder. Orthopedics,
32(11), 835.

